Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-11-22
2009-11-17
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S740000, C514S964000, C424S468000
Reexamination Certificate
active
07619007
ABSTRACT:
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
REFERENCES:
patent: 4346112 (1982-08-01), Henkel et al.
patent: 4812481 (1989-03-01), Reischig et al.
patent: 4861800 (1989-08-01), Buyske
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5061703 (1991-10-01), Bormann et al.
patent: 5162346 (1992-11-01), Lobisch et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5192550 (1993-03-01), Edgren et al.
patent: 5221536 (1993-06-01), Edgren et al.
patent: 5334618 (1994-08-01), Lipton
patent: 5358721 (1994-10-01), Edgren et al.
patent: 5382601 (1995-01-01), Nümberg et al.
patent: 5484608 (1996-01-01), Rudnic et al.
patent: 5648087 (1997-07-01), Ovaert et al.
patent: 5891885 (1999-04-01), Caruso
patent: 5912013 (1999-06-01), Rudnic et al.
patent: 5919826 (1999-07-01), Caruso
patent: 6187338 (2001-02-01), Caruso et al.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6217905 (2001-04-01), Edgren et al.
patent: 6284276 (2001-09-01), Rudnic et al.
patent: 6444702 (2002-09-01), Wang et al.
patent: 6491949 (2002-12-01), Faour et al.
patent: 6620845 (2003-09-01), Wang et al.
patent: 2003/0203055 (2003-10-01), Rao
patent: 2004/0122090 (2004-06-01), Lipton
patent: 2004/0224020 (2004-11-01), Schoenhard
patent: 2005/0031651 (2005-02-01), Gervais
patent: 2005/0065219 (2005-03-01), Lipton
patent: 2005/0124701 (2005-06-01), Went
patent: 2005/0208132 (2005-09-01), Sathyan et al.
patent: 2005/0209218 (2005-09-01), Meyerson
patent: 2005/0245460 (2005-11-01), Meyerson
patent: 2005/0245617 (2005-11-01), Meyerson et al.
patent: 2006/0052370 (2006-03-01), Meyerson
patent: 2006/0062851 (2006-03-01), Vergez
patent: 2006/0063810 (2006-03-01), Vergez
patent: 2006/0159763 (2006-07-01), Meyer
patent: 2006/0240043 (2006-10-01), Meyerson
patent: 2006/0252788 (2006-11-01), Went
patent: 0 451 484 (1991-10-01), None
patent: 0 452 484 (1991-10-01), None
patent: 0 502 642 (1992-09-01), None
patent: WO 89/09051 (1989-10-01), None
patent: WO 91/06291 (1991-05-01), None
patent: WO 91/14445 (1991-10-01), None
patent: WO 95/13796 (1995-05-01), None
patent: WO 97/14415 (1997-04-01), None
patent: WO 98/27961 (1998-07-01), None
patent: WO 00/18378 (2000-04-01), None
patent: WO 01/19901 (2001-03-01), None
patent: WO 01/32148 (2001-05-01), None
patent: WO 01/46291 (2001-06-01), None
patent: WO 2004/056335 (2004-07-01), None
patent: WO 2004/087116 (2004-10-01), None
patent: WO 2004/112768 (2004-12-01), None
patent: WO 2005/072705 (2005-08-01), None
patent: WO 2006/009769 (2006-01-01), None
patent: WO 2006/089494 (2006-08-01), None
patent: WO 2006/138227 (2006-12-01), None
Reisberg et al., “Memantine in moderate-to-severe alzheimer's disease”,N. Eng. J. Med., 348(14):1333-1341 (2003).
Greenberg et al., “Treatment of Major Depression and Parkinson's Disease with Combined Phenelzine and Amantadine”,Am. J. Psychiatry, 142(2):273-274 (1985).
Hovestadt, A.,J. Drug Ther. Res., 17(5):147-151 (Jun. 1992) (Article in Dutch with English summary only).
Jost, W.H., “Die Therapie der Fruhphase des idiopathischen Parkinson-Syndroms”,Nervenheikunde, 24:24-28 (2005) (Article in German with English summary only).
Rausch et al., “Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism”,J. Neural Transm., 32:269-275 (1990).
Siemers, E., “Recent progress in the treatment of Parkinson's disease”,Comprehensive Therapy, 18(9):20-24 (1992).
Parsons et al., “Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data”,Neuropharmacology, 38:735-767 (1999).
Namenda label, NDA 21-487, pp. 1-20.
Ditzler, K., Efficacy and Tolerability of Memantine in Patients with Dementia Syndrome, Arnzneim.-Forsch./Drug Res. 41 (II), Nr. 8, 773-780 (1991), Bad Krozingen, Germany.
Gortelmeyer, R. et al., Memantine in the Treatment of Mild to Moderate Dementia Syndrome, Arnzneim.-Forsh./ Drug Res. 42 (II), Nr. 7, 904-913 (1992), Frankfurt, Germany.
Winblad, B. et al., Memantine in Severe Dementia: Results of the 9M-Best Study (Benefit and Efficacy in Severly Demented Patients During Treatment with Memantine). Int. J. Geriat. Psychiatry 14, 135-146 (1999), John Wiley & Sons, Ltd.
Ho et al., Memantine: A New Treatment Option for Patients with Moderate-to-Severe Alzheimer's Disease, P&T, vol. 29 No. 3, Mar. 2004.
Orgogozo et al., Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia. A Randomized, Placebo-Controlled Trial (MMM 300), Stroke. 2002; 33(7):1834-9.
Wilcock et al., A Double-Blind, Placebo-Controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia (MMM500), Int Clin Psychopharmacol. 2002; 17(6):297-305.
Pantev et al., Clinical and Behavioural Evaluation in Long-Term Care Patients with Mild to Moderate Dementia Under Memantine Treatment, Zeitschrift fur Gerontopsychologie und psychiatrie, 6 (1993) Heft 2, S. 103-117.
Ambrozi and Danielczyk, Treatment of Impaired Cerebral Function in Psychogeriatric Patients with Memantine—Results of a Phase II Double-Blind Study, Pharmacopsychiat. 1988;21(3):144-6.
Rabey et al., Efficacy of Memantine, an NMDA Receptor Antagonist, in the Treatment of Parkinson's Disease (J Neural Transm. 1992; 4:277-82.
Edwards, New Studies on the Pharmacologic Treatment of Painful Neuropathies, Especially in Painful Diabetic Polyneuropathy, 52nd Annual Meeting of the American Academy of Neurology, Apr. 29-May 6, 2000, San Diego, CA, http://www.medscape.com/viewarticle/420246.
FDA Medical Review for Namenda® NDA 21-487, Oct. 2, 2003, pp. 1-113.
Bull, Drug review —Memantine, Drugs in Context 2005, I(I):1-40.
Chung et al., Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation, Br J Clin Pharmacol 1999, 48:678-87.
Grossmann et al., Memantine and neurogenic bladder disorders in spastic clinical pictures, Arzneim.-Forsch./Drug Res. 1982, 32(II)(10):1273-6.
Sansom, Oral extended-release products, Aust Prescr 1999, 22:88-90.
Fultz Timothy J.
Meyerson Laurence R.
Went Gregory T.
Adamas Pharmaceuticals, Inc.
Brouard Jan P.
Carter Kendra D
Padmanabhan Sreeni
LandOfFree
Method and composition for administering an NMDA receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for administering an NMDA receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for administering an NMDA receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4069556